Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.10M | -19.21M | -20.64M | -19.82M | -14.20M |
| Total Depreciation and Amortization | 1.06M | 1.60M | 1.72M | 2.00M | 1.94M |
| Total Amortization of Deferred Charges | -- | -- | -- | -464.30K | -222.70K |
| Total Other Non-Cash Items | 8.68M | 11.82M | 12.13M | 12.57M | 6.37M |
| Change in Net Operating Assets | 1.47M | 901.40K | 938.70K | -184.50K | 288.90K |
| Cash from Operations | -3.89M | -4.89M | -5.85M | -5.90M | -5.83M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Issued | 119.90K | 675.00K | 675.00K | 562.50K | 562.50K |
| Total Debt Repaid | -206.50K | -206.50K | -206.50K | -- | -- |
| Issuance of Common Stock | 4.11M | 5.57M | 6.70M | 5.25M | 3.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 0.00 | 1.15M | 1.55M | 2.30M |
| Repurchase of Preferred Stock | -- | -1.05M | -1.05M | -1.05M | -1.05M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.02M | 4.99M | 7.27M | 6.31M | 5.44M |
| Foreign Exchange rate Adjustments | -3.40K | -900.00 | 7.10K | -400.00 | -900.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.70K | 98.10K | 1.43M | 407.30K | -389.30K |